Non-Opioid Pain Management Solutions in Tucson, AZ

What I’d check before adding non opioid pain management here

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 11.5% of adults in Tucson have diagnosed diabetes — 0.5 points below the U.S. 12% figure. 15.7% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick non opioid pain management against that mix.

Cash PRP and Medicare CTPs in the same hallway

• Adult arthritis here is 23.9% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 15.7% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Arizona.
• Population 542,629 (Census city proper) understates metro demand and overstates how many of those people will ever see a biologic. Use it as scale, then underwrite against clinic specialty mix.
• Staff turnover in a city of 500k–1M makes “we trained them last year” a weak control. HCT/P handling, centrifuge SOPs, and wound-photo standards need a named owner in the practice, not a one-time in-service.

Uninsured mix and Medicare CTPs in the same building

JF reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Tucson is 11.5% or not. PLACES is planning data. The LCD is the claim.

How we’d stand this up in clinic